Høyvik AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, Peng Q, Wangen-Riise R, Wiig E, Ma LW, Revheim ME, Juzeniene A (2025)
Optimizing [²¹²Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts
J Nucl Med (in press)
DOI 10.2967/jnumed.125.270444, PubMed 41043994

Pharo H, Vedeld HM, Wahlqvist R, Lind GE (2025)
Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol 2025;88:23-30
Eur Urol (in press)
DOI 10.1016/j.eururo.2025.07.028, PubMed 40998632

Pfefferle A, Malmberg KJ (2025)
Rewiring natural killer cells for next-generation cancer therapies
Cancer Cell (in press)
DOI 10.1016/j.ccell.2025.08.007, PubMed 40972573

Emaldi M, Rey-Iborra E, Alamillo-Maeso P, Pulido R, Nunes-Xavier CE (2026)
Analysis of the Functional Impact of Glycosylation on Immune Checkpoint Proteins
Methods Mol Biol, 2959, 55-72
DOI 10.1007/978-1-0716-4734-9_4, PubMed 41028258

Rey-Iborra E, Emaldi M, Madariaga M, Pulido R, Nunes-Xavier CE (2026)
3D Spheroids to Study the Impact of Immune Checkpoint Proteins in Solid Tumors
Methods Mol Biol, 2959, 141-156
DOI 10.1007/978-1-0716-4734-9_10, PubMed 41028264

Scheiner B, Lombardi P, D'Alessio A, Kim G, Tafavvoghi M, Petrenko O, Goldin RD, Fulgenzi CAM, Torkpour A, Balcar L, Mauri FA, Pomej K, Himmelsbach V, Barsch M, Celsa C, Cabibbo G, Cheon J, Krall A, Hucke F, Di Tommaso L, Bernasconi M, Rimassa L, Samson A, Stefanini B, Mozayani B et al. (2025)
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
J Immunother Cancer, 13 (10)
DOI 10.1136/jitc-2024-010975, PubMed 41052886